Association between the Fatty Liver Index (FLI) and incident coronary heart disease: insights from a cohort study on the Chinese population

Association between the Fatty Liver Index (FLI) and incident coronary heart disease: insights from a cohort study on the Chinese population

BackgroundThe debate persists regarding whether metabolic dysfunction-associated steatotic liver disease (MASLD) actively contributes to coronary heart disease or merely acts as a passive indicator.ObjectiveThis research aims to clarify the relationship between liver fat accumulation, as quantified...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ying Miao, Yu Wang, Pijun Yan, Yi Li, Zhuang Chen, Nanwei Tong, Qin Wan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Endocrinology
Subjects:	the Fatty Liver Index coronary heart disease metabolic dysfunction-associated steatotic liver disease REACTION project Chinese population
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2024.1367853/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

TyG-BMI as a predictor of ischemic stroke over 10 years in middle-aged and older adults: findings from the China cardiometabolic disease and cancer cohort (4C) study
by: Ying Miao, et al.
Published: (2025-07-01)

The fibrosis-4 index and its association with carotid atherosclerosis in type 2 diabetes: a cross-sectional study in China
by: Ying Miao, et al.
Published: (2025-01-01)

Association of Circulating Omentin-1 with Osteoporosis in a Chinese Type 2 Diabetic Population
by: Pijun Yan, et al.
Published: (2020-01-01)

Ultrasound-guided caudal epidural block effectively reduces pain after abdominal and perineal surgeries in pediatric patients
by: Liang Nie, et al.
Published: (2025-05-01)

Unmet needs of metabolic dysfunction – Associated “fatty or steatotic” liver disease
by: Yu-Ming Cheng, et al.
Published: (2025-04-01)

The evolution of international definitions of fatty liver disease and insights into the working definition and features of the 2024 Chinese guideline
by: Li CHEN, et al.
Published: (2025-06-01)

Liver fibrosis increases the risk of subclinical atherosclerosis in patients with MASLD: a cross-sectional and longitudinal study
by: Haoyu Zhang, et al.
Published: (2025-07-01)

Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
by: Yu-Ming Cheng, et al.
Published: (2024-12-01)

Metabolic Dysfunction–Associated Steatotic Liver Disease, Alcohol Consumption, and the Risk of Atrial Fibrillation: A Nationwide Population‐Based Study
by: Minkwan Kim, et al.
Published: (2025-07-01)

Ketogenic diets and β-hydroxybutyrate in the prevention and treatment of diabetic kidney disease: current progress and future perspectives
by: Junle Li, et al.
Published: (2025-03-01)

Alnustone Ameliorates Metabolic Dysfunction‐Associated Steatotic Liver Disease by Facilitating Mitochondrial Fatty Acid β‐Oxidation via Targeting Calmodulin
by: Shourui Hu, et al.
Published: (2025-08-01)

Low-carbohydrate diets reduce cardiovascular risk factor levels in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials
by: Shanshan Pi, et al.
Published: (2025-08-01)

Fecal microbiota transplantation improves hepatic steatosis induced by HFD in a mouse model associated with liver ILC1 regulation and indole-3-carbinol level
by: Peng-fei Hou, et al.
Published: (2025-02-01)

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
by: K. L. Raikhelson, et al.
Published: (2024-05-01)

Bioactive metabolites: A clue to the link between MASLD and CKD?
by: Wen-Ying Chen, et al.
Published: (2025-01-01)

Social jetlag elicits fatty liver via perturbed circulating prolactin rhythm-mediated circadian remodeling of hepatic lipid metabolism
by: Peng-Zi Zhang, et al.
Published: (2025-06-01)

Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease
by: Zhifeng Gao, et al.
Published: (2025-01-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
by: Jaehyun Bae, et al.
Published: (2024-11-01)

Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease
by: Mei-jing Chen, et al.
Published: (2025-01-01)

FLI and FIB-4 in diagnosing metabolic dysfunction-associated steatotic liver disease in primary care: High prevalence and risk of significant disease
by: Mário Reis Álvares-da-Silva, et al.
Published: (2025-01-01)

Sequential Diagnostic Approach Using FIB-4 and ELF for Predicting Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Yeo-Wool Kang, et al.
Published: (2024-11-01)

Liver fibrosis progression analyzed with AI predicts renal decline
by: Dan-Qin Sun, et al.
Published: (2025-05-01)

Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study
by: Xianhua Mao, et al.
Published: (2025-07-01)

The association of chronic pain, painkiller use, and potential mediators with liver fat content
by: Yu Cheng, et al.
Published: (2025-02-01)

An updated systematic review and meta-analysis: correlation between circulating plasminogen activator inhibitor-1 levels and metabolic dysfunction-associated steatotic liver disease
by: Qicong Li, et al.
Published: (2025-08-01)

Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
by: Gong Feng, et al.
Published: (2025-03-01)

Exploring the epidemiology and awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among health sciences students in an academic health care institute in India
by: Umasankari S., et al.
Published: (2024-12-01)

Metabolic dysfunction-associated steatotic liver disease (MASLD) in children with obesity: An Obesity Medicine Association (OMA) and expert joint perspective 2025
by: Jennifer Panganiban, et al.
Published: (2025-06-01)

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study
by: Woo-Young Shin, et al.
Published: (2025-04-01)

Associations between cardiometabolic indices and the onset of metabolic dysfunction-associated steatotic liver disease as well as its progression to liver fibrosis: a cohort study
by: Ziping Song, et al.
Published: (2025-04-01)

Liver Stiffness, Not Steatosis, Predicts Mortality in MASLD Patients: An NHANES Analysis
by: Yuting Huang, et al.
Published: (2024-12-01)

Gut microbiota in liver diseases: initiation, development and therapy
by: Jian-Xiu Yu, et al.
Published: (2025-06-01)

Pachymaran alleviates fat accumulation, hepatocyte degeneration, and injury in mice with nonalcoholic fatty liver disease
by: Yu Hong, et al.
Published: (2025-07-01)

Transitioning from NAFLD to MAFLD and MASLD: the toxic relationship with alcohol consumption
by: Mubin Ozercan, et al.
Published: (2025-01-01)

Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
by: Seogsong Jeong, et al.
Published: (2025-04-01)

New steatotic liver disease criteria diagnostic performance in an agricultural population in Chile
by: Maria Spencer-Sandino, et al.
Published: (2025-07-01)

High-fat diet-induced liver injury in Channa argus through lipid metabolism, anti-oxidative status, apoptosis, and inflammation
by: Jiaxin Tian, et al.
Published: (2025-04-01)

Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
by: Seogsong Jeong, et al.
Published: (2025-04-01)

Impact of fatty liver index and metabolic dysfunction-associated steatotic liver disease on the risk of benign prostatic hyperplasia in older male adults
by: Fan Zhang, et al.
Published: (2025-08-01)

Circulating angiopoietin-like protein 8 (ANGPTL8) and steatotic liver disease related to metabolic dysfunction: an updated systematic review and meta-analysis
by: Farah Abdelhameed, et al.
Published: (2025-04-01)